title: Combined passive-active immunization against the hepatitis B virus of 132 newborns of chronic carrier mothers: long term results.
abstract: One hundred thirty-two newborns of carrier mothers were given combined passive-active immunization against the hepatitis B virus. Doses of hepatitis B immunoglobulin (HBIG) were 0.5 ml, and doses of vaccine (Heptavax B) were 10 micrograms. Schedules used were: HBIG, 0, 3 and 6 months and vaccine 1, 2 and 7 months (Schedule 1); HBIG, 0, 3 and 6 months, vaccine, 7, 8 and 13 months (Schedule 2); HBIG, 0 month and vaccine 1, 2 and 7 months (Schedule 3); HBIG, 0 month and vaccine 0, 1 and 6 months (Schedule 4). The study population consisted of 60 boys and 72 girls. Ethnic origins were the following: Haitian, 42; Cambodian, 33; French Canadian, 22; Vietnamese, 21; others, 14. Thirty-two children were born to hepatitis B e antigen-positive mothers. General outcome was: 121 became anti-hepatitis B surface antigen-positive; 5 became hepatitis B surface antigen-positive; and 6 remained negative for all markers (nonresponders). Sex, ethnic origin and immunization schedule had no influence on the outcome. Of the 32 children born to hepatitis B e antigen-positive mothers, only 4 became hepatitis B surface antigen-positive. In those who became anti-hepatitis B surface antigen-positive, mean serum anti-hepatitis B surface antigen antibody concentrations (log mIU/ml +/- SD) were: 3.47 +/- 1.03 at 8 to 9 months post-Vaccine 1; 2.89 +/- 0.91 at 14 to 17 months; 2.39 +/- 1.0 at 23 to 29 months; and 2.26 +/- 0.92 at 35 to 41 months.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Microbiology and Immunology, Hôpital Sainte-Justine, Montreal, Quebec, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Delage
authors.forename: S
authors.initials: S
authors.lastname: Rémy-Prince
authors.forename: S
authors.initials: S
authors.lastname: Ducic
authors.forename: E
authors.initials: E
authors.lastname: Pierri
authors.forename: S
authors.initials: S
authors.lastname: Montplaisir
mesh_terms: D002353:Carrier State; D002908:Chronic Disease; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007116:Immunization, Passive; D007231:Infant, Newborn; D008297:Male; D009035:Mothers; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage*
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines